Nektar Therapeutics has announced that it will host an investor call and live webcast to present top-line data from the 16-week induction period of its ongoing global Phase 2b REZOLVE-AD clinical trial. The study focuses on the investigational drug rezpegaldesleukin, a regulatory T-cell proliferator, aimed at treating moderate-to-severe atopic dermatitis. The presentation is scheduled for June 24, 2025, at 8:15am ET / 5:15am PT. Details for accessing the live webcast will be provided in a morning press release and on the company's website. A replay of the webcast will be available for at least 30 days following the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.